hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Chronic exposure to high level of nitrogen dioxide results in the allosteric inhibition of glutathione peroxidase and glutathione S-transferase, both of which are important enzymes found in the mucous membrane antioxidant defense system, that catalyse nucleophilic attack by reduced glutathione (GSH) on non-polar compounds that contain an electrophilic carbon and nitrogen. These inhibition mechanisms generates free radicals that causes peroxidation from the lipids in the mucous membrane leading to increased peroxidized erythrocyte lipids, a reaction that proceeds by a free radical chain reaction mechanism that result in oxidative stress. The oxidative stress on the mucous membrane causes the dissociation of the GSTp-JNK complex, oligomerization of GSTP and induction of the JNK pathway, resulting in apoptosis or inflammation of the bronchioles and pulmonary alveolus in mild cases. On migrating to the bloodstream, nitrogen dioxide poisoning results in an irreversible inhibition of the erythrocyte membrane acetylcholinesterase which may lead to muscular paralysis, convulsions, bronchoconstriction, the narrowing of the airways in the lungs (bronchi and bronchioles) and death by asphyxiation. It also causes a decrease in glucose-6-phosphate dehydrogenase which may results in glucose-6-phosphate dehydrogenase deficiency known as favism, a condition that predisposes to hemolysis (spontaneous destruction of red blood cells).
=== Development === On September 30, 2024, FX gave the project an 11-episode series order. The series is based on The Beauty, a creator-owned comic book written by Jeremy Haun and Jason A. Hurley and published by Image Comics. The original comic follows two detectives investigating a sexually transmitted disease that makes those infected physically beautiful but ultimately proves fatal due to side effects. Mac Quayle, a frequent collaborator with Murphy, composed the score for the series.
== Peptide fragmentation == Peptides are protonated in positive-ion mode. The proton initially locates at the N-terminus or a basic residue side chain, but because of the internal solvation, it can move along the backbone breaking at different sites which result in different fragments. The fragmentation rules are well explained by some publications. Three different types of backbone bonds can be broken to form peptide fragments: alkyl carbonyl (CHR-CO), peptide amide bond (CO-NH), and amino alkyl bond (NH-CHR).
=== Font === UPS commissioned brand consultancy FutureBrand to develop its own font, UPS Sans, for use in marketing and communication material. UPS Sans was created by slightly altering certain parts of FSI FontShop International's font FF Dax without permission. This has resulted in an agreement between FSI FontShop International and FutureBrand to avoid litigation.
Once again, the German armies have invaded by force the territory of a neutral country, abusing its military potential. (...) For those who still think that neutrality is a guarantee of peace and salvation, the case of these two nations, small for their territory, but great for their sense of dignity and for their generous love of independence and sovereignty, should serve as an example and also as an encouragement. In April 1941, Avila Camacho ordered the seizure of German and Italian ships in national ports; among the ships thus seized was the Italian-flagged tanker Lucifero, which would later be called Potrero del Llano. It became evident that the government of Avila Camacho maintained a "simulated neutrality"; Mexico's material support was clearly for the Allied side. Two months later, another decree was published prohibiting the export of Mexican products to countries outside the American continent. This decision primarily affected Mexican oil, whose only major buyer would then be the United States, a country with which political tension was beginning to dissipate as the U.S. arms industry now required Mexico's raw material. On December 7, 1941, the Imperial Japanese Navy attacked Pearl Harbor, precipitating the Americans to abandon neutrality and enter the war which, from being purely European, thus became world-wide. Mexico, respecting the agreement of the Havana Conference of 1940, broke off relations with Japan and suspended all commercial exchanges with the Axis countries.
Sources: en.wikipedia.org
== History == The femtosecond lenticule extraction (FLE then FLEx) procedure was first introduced at the American Academy of Ophthalmology Annual Meeting in 2006 by Walter Sekundo and Marcus Blum, and was first published in 2008 by Walter Sekundo et al.The small incision lenticule extraction (SMILE) procedure was first published in 2011 by Walter Sekundo et al. Various modifications of the procedure have since then been described which aim to reduce the duration of the procedure, reduce the risks of the lenticules being incorrectly cut or make the procedure easier to learn.
The combat of Trails is turn-based with tactical elements. Unlike most other turn-based games, the series lacks random encounters as most enemies are visible on the overworld. Combat takes place on a large grid, with characters only able to move across a set number of squares or perform a single ability each turn. Turns are listed on a timeline on the screen, which can be manipulated with certain abilities. In addition to basic attacks and item usage, every character has abilities known as Crafts and Arts. Crafts are unique to each character and are usually unlocked or strengthened by leveling up. S-Crafts are a character's ultimate ability fueled by a meter that builds as they deal and take damage. When full, players can use it at any time to bypass the turn order to perform skills such as dealing large amounts of damage or supporting their party with healing and buffs. Arts are magic-like spells that are powerful but take time to cast. Rather than being unique to any specific character or monster like Crafts, Arts are determined by the type and specific arrangement of Quartz, items similar to Materia from Final Fantasy VII. Each successive game usually introduces new gameplay mechanics, such as the addition of Persona-like social events in Trails of Cold Steel or the optional action-based combat system in Trails Through Daybreak.
Individuals sometimes label themselves "vegetarian" while practicing a semi-vegetarian diet, as some dictionary definitions describe vegetarianism as sometimes including the consumption of fish, or only include mammalian flesh as part of their definition of meat, while other definitions exclude fish and all animal flesh. In other cases, individuals may describe themselves as "flexitarian". These diets may be followed by those who reduce animal flesh consumed as a way of transitioning to a complete vegetarian diet or for health, ethical, environmental, or other reasons. Semi-vegetarian diets include:
=== Pakistan === Pizza Hut Pakistan (Urdu: پیزاہٹ پاکستان) is the Pakistani franchisee of Pizza Hut. It is owned by MCR (Pvt) Ltd and is headquartered in Karachi, Pakistan. The first outlet was opened in Karachi in 1993. Currently, Pizza Hut has a presence in 23 major cities.
=== Education === Kopeček graduated with his M.S. in macromolecular chemistry from the Institute of Chemical Technology in Prague, Czechoslovakia, in 1961. He then received his Ph.D. in macromolecular chemistry from the Institute of Macromolecular Chemistry at the Czechoslovak Academy of Sciences in Prague in 1965. In 1967, Kopeček pursued postdoctoral studies at the National Research Council of Canada in the Division of Applied Chemistry in Ottawa. In 1990 Kopeček received his D.Sc. in chemistry from the Czechoslovak Academy of Sciences. During his time in graduate school, he was mentored by professors Drahoslav Lim and Otto Wichterle, who invented hydrogels and created soft contact lenses. Kopeček received an honorary Ph.D. from the University of Helsinki in Finland in 2014.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.